CL2021003341A1 - Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos. - Google Patents
Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos.Info
- Publication number
- CL2021003341A1 CL2021003341A1 CL2021003341A CL2021003341A CL2021003341A1 CL 2021003341 A1 CL2021003341 A1 CL 2021003341A1 CL 2021003341 A CL2021003341 A CL 2021003341A CL 2021003341 A CL2021003341 A CL 2021003341A CL 2021003341 A1 CL2021003341 A1 CL 2021003341A1
- Authority
- CL
- Chile
- Prior art keywords
- pyrazolopyrimidine
- sulfone
- kinase inhibitors
- jak kinase
- jak
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
Abstract
En el presente documento se describen compuestos de fórmula, en los que R1, R2, R3, R4, R5 y R6 son como se definen en el presente documento, y sales de los mismos que son útiles como inhibidores de JAK cinasas. Además, se proporcionan composiciones farmacéuticas que incluyen dicho inhibidor de JAK y un portador, adyuvante o portador farmacéuticamente aceptable, y procedimientos para tratar o disminuir la gravedad de una enfermedad o afección sensible a la inhibición de la actividad de una Janus cinasa en un paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019091712 | 2019-06-18 | ||
US202063035381P | 2020-06-05 | 2020-06-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021003341A1 true CL2021003341A1 (es) | 2022-07-22 |
Family
ID=71575774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021003341A CL2021003341A1 (es) | 2019-06-18 | 2021-12-14 | Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos. |
Country Status (17)
Country | Link |
---|---|
US (2) | US11453671B2 (es) |
EP (1) | EP3986901A1 (es) |
JP (1) | JP2022537964A (es) |
KR (1) | KR20220024405A (es) |
CN (1) | CN114008051A (es) |
AU (1) | AU2020297415A1 (es) |
BR (1) | BR112021025618A2 (es) |
CA (1) | CA3140024A1 (es) |
CL (1) | CL2021003341A1 (es) |
CO (1) | CO2022000118A2 (es) |
CR (1) | CR20210661A (es) |
IL (1) | IL288957A (es) |
MA (1) | MA56518A (es) |
MX (1) | MX2021015319A (es) |
PE (1) | PE20220577A1 (es) |
TW (1) | TW202115068A (es) |
WO (1) | WO2020257145A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023218484A1 (en) | 2022-05-11 | 2023-11-16 | Pi Industries Ltd. | Bicyclic compounds and their use as pest control agents |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
JPH11508583A (ja) | 1995-07-06 | 1999-07-27 | ゼネカ・リミテッド | ペプチド系のフィブロネクチン阻害薬 |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
DE60214428T2 (de) | 2001-12-20 | 2007-09-20 | Bayer Healthcare Ag | 1, 4-dihydro-1, 4-diphenylpyridin-derivate |
SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
CN101616921A (zh) * | 2007-01-30 | 2009-12-30 | 比奥根艾迪克Ma公司 | 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途 |
JP2010532312A (ja) * | 2007-01-30 | 2010-10-07 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 1−h−ピラゾロ(3,4b)ピリミジン誘導体および有糸分裂キナーゼの調節剤としてのその使用 |
RU2560153C2 (ru) | 2008-06-20 | 2015-08-20 | Дженентек, Инк. | Триазолпиридиновые соединения, ингибирующие jak, и способы |
MX2011004494A (es) | 2008-10-31 | 2011-05-24 | Genentech Inc | Compuestos de pirazolopirimidina inhibidores de jak y metodos. |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
KR20150079968A (ko) | 2012-11-09 | 2015-07-08 | 자코버스 파마슈티컬 컴패니, 인코포레이티드 | 헤테로아릴 유도체 및 그의 용도 |
US9346815B2 (en) | 2014-05-23 | 2016-05-24 | Genentech, Inc. | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof |
TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
EP3416967B1 (en) * | 2016-02-18 | 2022-02-09 | F. Hoffmann-La Roche AG | Therapeutic compounds, compositions and methods of use thereof |
JP6900491B2 (ja) | 2016-12-29 | 2021-07-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ピラゾロピリミジン化合物及びその使用方法 |
JP2020510061A (ja) | 2017-03-14 | 2020-04-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ピラゾロクロロフェニル化合物、組成物及びその使用方法 |
US20180334465A1 (en) | 2017-05-22 | 2018-11-22 | Genentech, Inc. | Therapeutic compounds and compositions, and methods of use thereof |
WO2018215389A1 (en) | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
EP3740488A1 (en) | 2018-01-15 | 2020-11-25 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine compounds as jak inhibitors |
TW202115069A (zh) | 2019-06-18 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | Jak激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途 |
JP2022537354A (ja) | 2019-06-18 | 2022-08-25 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Jakキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用 |
-
2020
- 2020-06-16 AU AU2020297415A patent/AU2020297415A1/en not_active Abandoned
- 2020-06-16 US US16/902,499 patent/US11453671B2/en active Active
- 2020-06-16 WO PCT/US2020/037853 patent/WO2020257145A1/en unknown
- 2020-06-16 EP EP20739492.5A patent/EP3986901A1/en active Pending
- 2020-06-16 CA CA3140024A patent/CA3140024A1/en active Pending
- 2020-06-16 CN CN202080044750.2A patent/CN114008051A/zh active Pending
- 2020-06-16 JP JP2021574283A patent/JP2022537964A/ja active Pending
- 2020-06-16 KR KR1020227000044A patent/KR20220024405A/ko active Search and Examination
- 2020-06-16 MX MX2021015319A patent/MX2021015319A/es unknown
- 2020-06-16 TW TW109120272A patent/TW202115068A/zh unknown
- 2020-06-16 PE PE2021002182A patent/PE20220577A1/es unknown
- 2020-06-16 CR CR20210661A patent/CR20210661A/es unknown
- 2020-06-16 BR BR112021025618A patent/BR112021025618A2/pt unknown
- 2020-06-16 MA MA056518A patent/MA56518A/fr unknown
-
2021
- 2021-12-13 IL IL288957A patent/IL288957A/en unknown
- 2021-12-14 CL CL2021003341A patent/CL2021003341A1/es unknown
-
2022
- 2022-01-12 CO CONC2022/0000118A patent/CO2022000118A2/es unknown
- 2022-08-24 US US17/821,851 patent/US20230016791A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN114008051A (zh) | 2022-02-01 |
KR20220024405A (ko) | 2022-03-03 |
CA3140024A1 (en) | 2020-12-24 |
JP2022537964A (ja) | 2022-08-31 |
CR20210661A (es) | 2022-02-11 |
CO2022000118A2 (es) | 2022-01-28 |
PE20220577A1 (es) | 2022-04-20 |
AU2020297415A1 (en) | 2022-01-06 |
US11453671B2 (en) | 2022-09-27 |
EP3986901A1 (en) | 2022-04-27 |
MX2021015319A (es) | 2022-04-07 |
US20200399275A1 (en) | 2020-12-24 |
WO2020257145A1 (en) | 2020-12-24 |
BR112021025618A2 (pt) | 2022-02-01 |
TW202115068A (zh) | 2021-04-16 |
US20230016791A1 (en) | 2023-01-19 |
MA56518A (fr) | 2022-04-27 |
IL288957A (en) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
CU20210015A7 (es) | COMPUESTOS DE PIRAZOLO [3.4-b] PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
ECSP12011645A (es) | Compuestos y métodos inhibidores de jak de pirazolopirimidina | |
UY36371A (es) | Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec | |
AR111233A1 (es) | Inhibidores de tyk2, usos y métodos para la producción de los mismos | |
CO2019010559A2 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos | |
CL2012000589A1 (es) | Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras. | |
NI201600089A (es) | Análogos de cortistatina y síntesis y usos de los mismos | |
EA201792116A1 (ru) | Ингибитор янус-киназы | |
UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
CO2019012571A2 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
WO2017089390A8 (en) | Janus kinases inhibitors, compositions thereof and use thereof | |
CR20110224A (es) | Pirazolopirimidina inhibidor jak compuestos y metodos | |
UY27714A1 (es) | 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos. | |
CR20170092A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
CL2021000844A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
CL2021003341A1 (es) | Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos. | |
CO2021001925A2 (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 | |
PE20191715A1 (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
CO2021000782A2 (es) | Agentes inhibidores de ask1 | |
BR112022021735A2 (pt) | Compostos úteis para inibir cinase ret |